Mirum Pharmaceuticals (MIRM) Expected to Announce Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $98.47 million for the quarter.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. The business had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company's revenue for the quarter was up 61.2% on a year-over-year basis. During the same period last year, the company earned ($0.54) EPS. On average, analysts expect Mirum Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mirum Pharmaceuticals Trading Down 2.1 %

Shares of MIRM stock traded down $0.97 on Friday, hitting $44.27. 653,782 shares of the stock traded hands, compared to its average volume of 525,466. Mirum Pharmaceuticals has a twelve month low of $23.83 and a twelve month high of $54.23. The stock has a market capitalization of $2.19 billion, a PE ratio of -21.92 and a beta of 0.95. The firm's 50-day moving average price is $42.82 and its two-hundred day moving average price is $44.22. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Insider Transactions at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 27,279 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the transaction, the chief executive officer now owns 138,641 shares in the company, valued at approximately $6,129,318.61. The trade was a 16.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Jolanda Howe sold 57,606 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the sale, the senior vice president now owns 4,841 shares in the company, valued at approximately $214,698.35. This represents a 92.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 92,764 shares of company stock valued at $4,109,161. 22.87% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

MIRM has been the subject of several analyst reports. HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research note on Friday, February 28th. JMP Securities raised their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research note on Friday. Finally, Robert W. Baird upped their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $59.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.